Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
arcticnovartis
Thu, 10/16/2025 – 07:19
Read more about Novartis Fabhalta® (iptacopan) meets Phase III primary e…
Entries by arcticnovartis
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
arcticnovartis
Tue, 09/30/2025 – 22:19
Read more about Novartis receives FDA approval for Rhapsido® (remibr…
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
arcticnovartis
Mon, 09/29/2025 – 14:19
Read more about Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
…
Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis
Mon, 09/29/2025 – 13:49
Read more about Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025&nb…
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
arcticnovartis
Fri, 09/26/2025 – 07:19
Read more about Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO…
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
arcticnovartis
Wed, 09/24/2025 – 08:34
Read more about New Novartis data further support benefits of Kesimpta® in relaps…
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
arcticnovartis
Tue, 09/09/2025 – 07:04
Read more about Novartis to acquire Tourmaline Bi…
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
arcticnovartis
Sat, 08/30/2025 – 17:04
Read more about Novartis Leqvio® shows statistically significant and clinically m…
New Novartis ESC data highlights strength of cardiovascular portfolio
arcticnovartis
Mon, 08/18/2025 – 07:19
Read more about New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE
PrintPDF
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis
Tue, 08/12/2025 – 07:19
Read more about Novartis ianalumab Phase III trial meets prim…